His scientific interests lie mostly in COPD, Internal medicine, Exacerbation, Randomized controlled trial and Cardiology. He has included themes like FEV1/FVC ratio, Intensive care medicine, Lung, Severity of illness and Spirometry in his COPD study. His research investigates the link between Internal medicine and topics such as Physical therapy that cross with problems in Placebo.
His work carried out in the field of Exacerbation brings together such families of science as Eosinophil, Heart failure and Fluticasone propionate. His biological study spans a wide range of topics, including Endobronchial valve, Oncology, Mortality rate, Minimal clinically important difference and Collateral ventilation. His Vilanterol research includes elements of Clinical endpoint and Pneumonia.
His primary areas of investigation include COPD, Internal medicine, Cardiology, Exacerbation and Pulmonary disease. His research in COPD intersects with topics in Vilanterol, FEV1/FVC ratio, Intensive care medicine, Physical therapy and Cohort. His research on Internal medicine frequently connects to adjacent areas such as Gastroenterology.
His Cardiology study combines topics from a wide range of disciplines, such as Airflow obstruction and Surgery. His Exacerbation study frequently draws connections to other fields, such as Randomized controlled trial. His Pulmonary disease study frequently draws connections between adjacent fields such as MEDLINE.
Mark T. Dransfield mostly deals with Internal medicine, COPD, Pulmonary disease, Cardiology and Exacerbation. He usually deals with Internal medicine and limits it to topics linked to Gastroenterology and Chronic bronchitis. He merges COPD with In patient in his study.
His Pulmonary disease research also works with subjects such as
His main research concerns COPD, Internal medicine, Pulmonary disease, Exacerbation and Intensive care medicine. His study in COPD focuses on Obstructive lung disease in particular. His Internal medicine study integrates concerns from other disciplines, such as Pectoralis Muscle and Cardiology.
His Pulmonary disease study combines topics in areas such as Disease progression, MEDLINE, Acute care, Healthcare utilization and Intensive care unit. His work deals with themes such as Body mass index, Precision medicine, Chronic bronchitis, Diagnostic biomarker and Lung function, which intersect with Exacerbation. His work carried out in the field of Intensive care medicine brings together such families of science as Asthma and Respiratory system.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Azithromycin for Prevention of Exacerbations of COPD
Richard K. Albert;Richard K. Albert;John Connett;William C. Bailey;Richard Casaburi.
The New England Journal of Medicine (2011)
The national lung screening trial: Overview and study design
Constantine A. Gatsonis;Denise R. Aberle;Christine D. Berg;William C. Black.
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials
Steven Pascoe;Nicholas Locantore;Mark T Dransfield;Mark T Dransfield;Neil C Barnes;Neil C Barnes.
The Lancet Respiratory Medicine (2015)
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
David A. Lipson;Frank Barnhart;Noushin Brealey;Jean Brooks.
The New England Journal of Medicine (2018)
Pulmonary arterial enlargement and acute exacerbations of COPD.
J. Michael Wells;George R. Washko;Mei Lan K. Han;Naseer Abbas.
The New England Journal of Medicine (2012)
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials
Mark T Dransfield;Jean Bourbeau;Paul W Jones;Nicola A Hanania.
The Lancet Respiratory Medicine (2013)
Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD
G. J. Criner;John E Connett;S. D. Aaron;R. K. Albert.
The New England Journal of Medicine (2014)
Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline
Gerard J. Criner;Jean Bourbeau;Rebecca L. Diekemper;Daniel R. Ouellette.
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.
MeiLan K. Han;Hana Muellerova;Douglas Curran-Everett;Mark T. Dransfield.
The Lancet Respiratory Medicine (2013)
Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD.
Mark T Dransfield;Steven M Rowe;James E Johnson;William C Bailey.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: